S-3 filed May 19, 2026 at 12:03 ET
PepGen filed a new universal shelf registration statement (S-3) for up to $400M in securities, including a $100M ATM facility with Stifel that replaces a prior ATM with $88.5M remaining capacity. The filing comes 7 days after the company reported a Q1 2026 net loss of $17.8M and cash of $132.3M (sufficient into 2H 2027), with an unresolved FDA partial clinical hold on its lead DM1 candidate. The massive increase in authorized ATM capacity ($88.5M remaining → $100M new + $300M other shelf) signals management's expectation of needing significant capital beyond current runway to fund operations through clinical milestones, creating material dilution risk for existing shareholders.